Author(s)

Iskander Al-Githmi

Department of Surgery, Division of Cardiothoracic Surgery, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.

Introduction: Lung transplant is the preferred treatment for several end-stage pulmonary diseases. The first successful human lung transplant was performed by the Toronto Group in 1983 [1]. Objectives: This article discusses our initial experience with single and double lung transplant. Study Design: A retrospective analysis was done on 11 consecutive lung transplants for end-stage pulmonary diseases performed at our institution between 2008 and 2010. Materials and Methods: Major indications were idiopathic pulmonary fibrosis (n = 6), bronchiectasis (n = 2), primary pulmonary hypertension (n = 1), lymphangioleiomyomatosis (n = 1), and scleroderma (n = 1). Results: Two patients (18.2%) died within 30 days of surgery. One- and 2-year survival rates for the recipients were 81.8% and 72.7%. Sepsis caused the deaths of 2 recipients. Conclusions: Although sepsis and chronic rejection limit the benefits, lung transplant gives many patients with end-stage pulmonary disease the ability for a better quality of life.

Lung; Transplant; Outcomes

I. Al-Githmi, "Lung Transplant and Outcomes: A Single-Center Experience," Surgical Science, Vol. 3 No. 6, 2012, pp. 314-317. doi: 10.4236/ss.2012.36062.